Holders — by stockHoldings — by fund
GSK plc
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001131399
$602.2M
disclosed book value
13
positions
29.2%
largest position share
Positions, as of 2026-06-30
top 13 of 13 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | CRISPR THERAPEUTICS AG | 3.2M | $175.7M | 29.2% |
| 2 | WAVE LIFE SCIENCES LTD | 18.2M | $106.0M | 17.6% |
| 3 | VIRVIR BIOTECHNOLOGY INC | 8.6M | $87.1M | 14.5% |
| 4 | BNTXBIONTECH SE | 889,824 | $82.8M | 13.7% |
| 5 | IDYAIDEAYA BIOSCIENCES INC | 1.3M | $49.7M | 8.3% |
| 6 | CYTKCYTOKINETICS INC | 340,434 | $29.0M | 4.8% |
| 7 | LYELLYELL IMMUNOPHARMA INC | 1.5M | $21.3M | 3.5% |
| 8 | SPROSPERO THERAPEUTICS INC | 9.2M | $20.3M | 3.4% |
| 9 | NKTXNKARTA INC | 3.2M | $8.9M | 1.5% |
| 10 | FULCFULCRUM THERAPEUTICS INC | 1.8M | $6.5M | 1.1% |
| 11 | BCYCBICYCLE THERAPEUTICS PLC | 1.5M | $6.5M | 1.1% |
| 12 | CVRXCVRX INC | 1.0M | $5.2M | 0.9% |
| 13 | RGNXREGENXBIO INC | 271,456 | $3.3M | 0.5% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.